Across TCGA pan-cancer cohorts, RPL17-C18orf32 RNA is linked to patient survival in 22 of 34 cancer types, making it the most broadly survival-associated RPL17-C18orf32 data layer.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher RPL17-C18orf32 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated RPL17-C18orf32 expression acts as an unfavorable survival marker, although some lineages such as BRCA and GBM show a favorable association.
HNSC, BRCA, and ACC are the cancer types where RPL17-C18orf32 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.